Andere talen Revvity, Inc.

Aandelen

Beurs gesloten - Nyse Andere beurzen 22:00:02 31-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
109,3 ^USD	+0,85%		-3,54%	-0,05%

14/05	Transcript : Revvity, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:40 AM
30/04	REVVITY, INC. : TD Cowen ontvangt een koopadvies	ZM

Transcript : Revvity, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:40 AM	14/05
REVVITY, INC. : TD Cowen maintient sa recommandation à l'achat	30/04
REVVITY, INC. : JPMorgan Chase est neutre sur le titre	30/04
REVVITY, INC. : Baird maintient sa recommandation à l'achat	30/04
REVVITY, INC. : Bernstein favorable sur le dossier	30/04
REVVITY, INC. : Nephron Research à l'achat	29/04
Transcript : Revvity, Inc., Q1 2024 Earnings Call, Apr 29, 2024	29/04
Revvity beats quarterly estimates on demand for diagnostic equipment	29/04
Revvity Q1 Adjusted Earnings, Revenue Down; Lowers 2024 Revenue Guidance	29/04
Revvity, Inc. Updates Earnings Guidance for the Full Year 2024	29/04
Revvity, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024	25/04
Early Check Newborn Screening Study Taps Revvity to Provide Genome Sequencing	25/04
Revvity Unveils A New Era of Automated Tuberculosis Testing	24/04
REVVITY, INC. : Bernstein toujours neutre sur le dossier	23/04
REVVITY, INC. : Baird favorable sur le dossier	23/04
U.S. Currency	18/04	FA
Revvity Says Court Issued Preliminary Injunction Against Cloud Software Group	02/04
Revvity Files Lawsuit Against Partner Cloud Software Group, Reaffirms 2024 Guidance	20/03
Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024	20/03

Geen resultaten voor deze zoekopdracht